Trade PROCEPT BioRobotics Corp - PRCT CFD

Trading Conditions

• TypeThis financial instrument is available for trading through CFDs and Knock-outs.Knock-out options available only for selected countries.Learn more about:CFDsKnock-outs:
  CFD

  

  Knock-out

  
• Spread: 0.15
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021485 %(-$1.07)Trade size with leverage ~ $5,000.00Money from leverage ~$4,000.00Go to platform: -0.02149%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000738 %(-$0.04)Trade size with leverage ~ $5,000.00Money from leverage ~$4,000.00Go to platform: -0.00074%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 20.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021485 %
  (-$1.07)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000738 %
  (-$0.04)

Key Stats

• Prev. Close: 20.31
• Open: 21.09
• 1-Year Change: -43.15%
• Day's Range: 20.62 - 21.11

Trade PROCEPT BioRobotics Corp - PRCT

About Procept Biorobotics Corp

Procept Biorobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). Its AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. It designs Aquablation therapy to deliver outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Procept Biorobotics Corp revenues increased from $7.7M to $34.5M. Net loss increased 13% to $59.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Interest expense increase of 10% to $5.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.25 to -$1.38.